# A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

> **NCT04115631** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 360 (actual)

## Conditions studied

- Liver Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Bendamustine
- **DRUG:** Bendamustine Hydrochloride
- **DRUG:** Cytarabine
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT04115631
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-13
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04115631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04115631, "A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04115631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*